Preliminary results were presented at the annual meeting of the Centers for Birth Defects Research and Prevention (San Antonio, TX; November 11, 2004) and at the annual Maternal and Child Health Epidemiology Conference (Atlanta, GA; December 7, 2006).
1542-0760/asset/olbannerleft.gif?v=1&s=e419a8a011f7957f0f17a7d0b0f4ca19f1fa5195)
1542-0760/asset/olbannerright.gif?v=1&s=62e62a3884754a64e443c69910c285dd97e23e41)
Original Article
You have free access to this content
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects†‡
Article first published online: 19 NOV 2011
DOI: 10.1002/bdra.22865
Copyright © 2011 Wiley Periodicals, Inc.
Issue
Birth Defects Research Part A: Clinical and Molecular Teratology
Volume 94, Issue 1, pages 22–30, January 2012
Additional Information
How to Cite
Anderka, M., Mitchell, A. A., Louik, C., Werler, M. M., Hernández-Diaz, S., Rasmussen, S. A. and the National Birth Defects Prevention Study (2012), Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 94: 22–30. doi: 10.1002/bdra.22865
- †
- ‡
This study was supported by a grant from the Centers for Disease Control and Prevention (U50/CCU 113247), by a New Investigator in MCH Research Dissertation Award from MCHB, HHS (1 R03 MC 00004); and by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (RO1 HD 046595). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Massachusetts Department of Public Health.
Publication History
- Issue published online: 10 JAN 2012
- Article first published online: 19 NOV 2011
- Manuscript Accepted: 30 AUG 2011
- Manuscript Revised: 27 AUG 2011
- Manuscript Received: 18 JUL 2011
Funded by
- Centers for Disease Control and Prevention. Grant Number: U50/CCU 113247
- New Investigator in MCH Research Dissertation Award from MCHB. Grant Number: HHS (1 R03 MC 00004)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development. Grant Number: RO1 HD 046595
REFERENCES
- American College of Obstetrics and Gynecology. 2004. ACOG Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol 103: 803–814.
- ,,, et al. 2002. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can 24: 817–823.
- ,,, et al. 2005. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 61: 899–906.
- ,. 2003. Over-the-counter medications in pregnancy. Am Fam Physician 67: 2517–2524.
- ,,, et al. 1999. Nausea during pregnancy and congenital health defects: a population-based case-control study. Am J Epi 149: 717–725.
- ,,, et al. 2005. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 105: 849–856.
- . 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 9: 337–349.
- ,,, et al.; National Birth Defects Prevention Study. 2009. Maternal corticosteroid use and hypospadias. J Pediatr 155: 39–44.
- ,,, et al.; National Birth Defects Prevention Study. 2007. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197: 585.e1–e7.
- ,,, et al. 2000. Risk factors for cytogenetically normal holoprosencephaly in California: a population-based case-control study. Am J Med Genet 90: 320–325.
- . 1992. Conception, implantation, placentation and embryology. In: The Merck manual of diagnosis and therapy: volume II—specialties. Rahway, NJ: Merck Research Laboratories, pp. 74–76.
- ,,, et al. 2010. Optimal management of nausea and vomiting of pregnancy. Int J Womens Health 2: 241–248.
- ,,, et al. 2007. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician 53: 2109–2111.
- ,,, et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparison study. Br J Obstet Gynaecol 111: 940–943.
- ,,. 2001. Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Obstet Gynecol Surv 56: 775–782.
- ,,, et al.; National Birth Defects Prevention Study. 2009. Orofacial clefts in the National Birth Defects Prevention Study, 1997–2004. Am J Med Genet A 149A: 1149–1158.
- ,,, et al.; National Birth Defects Prevention Study. 2009. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol l85: 137–150.
- ,. 2007. The safety of drugs for the treatment of nausea and vomiting of pregnancy. Expert Opin Drug Saf 6: 685–694.
- ,,, et al. 2009. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 104: 1541–1545.
- . 2001. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed in pregnancy. Eur J Obstet Gynaecol Reprod Biol 96: 63–68.
- . 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Brit J Obstet Gynaecol 105: 877–881.
- ,,, et al. 2010. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 203: 571.e1–e7.
- ,,, et al. 1994. On the use of affected controls to address recall bias in case-control studies of birth defects. Teratology 49: 273–281.
- ,,, et al. 1998. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 179: 727–730.
- ,,, et al. 1997. Prenatal exposure to salicylates and gastroschsis: a case-control study. Teratology 56: 241–243.
- ,,, et al. 2009. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 360: 2528–2535.
- . 2010. Proton pump inhibitors and birth defects—some reassurance, but more needed. N Engl J Med 363: 2161–2163.
- ,,, et al. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 47: 1526–1529.
- ,,, et al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385–392.
- ,. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 363: 2114–2123.
- ,,, et al. 2003. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol 189: 1374–1377.
- ,,, et al. 2003. Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 67: 968–970.
- ,,, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67: 193–201.
- ,,, et al. 1999. Use of cimetidine, omeprazole and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150: 476–481.
- . 2000. Nausea and vomiting in pregnancy and pregnancy outcome: an epidemiologic overview. In: Koren G,Bishai R, editors. Nausea and vomiting of pregnancy: state of the art. Vol 1. Toronto, Canada: Motherisk, pp 41–46.
- ,,, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116( Supp 1): 32–40.